Minimally Invasive Circulatory Assist Devices

Product Summary

Second Heart is developing a minimally invasive circulatory support platform based on proprietary aortic stent pump technology. The platform will be deployed using low profile catheter-based techniques and will provide either temporary or chronic circulatory support, depending on the specific needs of the patient. Second Heart’s initial product will be a catheter-based temporary assist pump to treat patients with acute decompensated heart failure and to provide circulatory support to those undergoing high-risk percutaneous coronary intervention (PCI). The second application will be a wirelessly powered circulatory assist pump that will provide chronic circulatory support for heart failure patients.

Key features of Second Heart’s platform include:

  • A higher flow (with lower RPMs) rate than other systems at over 7 liters per minute.
  • Pump placement just above the renal arteries will provide additional benefit for heart failure patients with kidney dysfunction.
  • A choice of pulsatile or continuous flow to optimize hemodynamics and lessen the risk of thrombosis.
  • The only system to use the full inner diameter of the aorta to increase pump stability and reduce pump migration.
  • Lower risk of mechanical failure due to simple impeller deployment mechanism, improved bearings, and liquid cooled drive shaft.

Latest News

Second Heart Assist, Inc. Files Patent Application On Real Time Auto Adjust Management Of Circulatory Assist Support Based On Implanted Wireless Sensors

June 8, 2018 | By Api Podder Invention provides auto adjustment of impeller speed and pulsating cuff pulsations based on real time pressure differentials and other data from implanted sensors placed in strategic positions. This invention is designed to optimize flow...

1st Large Animal Implant Study

1st Large Animal Implant Study Tufts Medical Center - Summer 2017 Second Heart Assist, Inc. Temporary Use Circulatory Assist...

LEONHARDT’S LAUNCHPADS EXPANDS PATENT ESTATE WITH OPTION TO EXCLUSIVE LICENSE AGREEMENT WITH CALTECH

Press Release – March 22nd, 2017 – Santa Monica, CA, Pasadena, CA, Salt Lake City, Utah.–(PRBUZZ)— Leonhardt’s Launchpads, a Santa Monica, California and Salt Lake City, Utah based innovation accelerator focused on organ regeneration and recovery technologies...

Leonhardt’s Launchpads Chooses Biomerics To Provide Contract Manufacturing and Engineering Design Services For Medical Devices

Press Release – March 14th, 2017 – (PRBUZZ) – Salt Lake City, Utah, Santa Monica, CA and Brooklyn Park, Minnesota – Today Leonhardt’s Launchpads announced it has selected Biomerics LLC Utah and Biomerics Advanced Catheter Minnesota as its primary source manufacturer...

OUR TEAM

Alex Richardson
VP Engineering & Product Development

Asli Gozoren
Chief Advisor, Investor Relations

Brittany Brown
Board Director

Dinesh Patel
Board Director

Howard Leonhardt
Chairman, CEO

Jane Reedy
Chief Advisor Clinical Affairs

Jeff Donofrio
President

Ken Evans
VP Corporate Development, Board Director

Kurt Kruger
Chief Advisor Biomedical Engineering & Finance

Larry Stevens
Chief Advisor Regulatory Affairs

Leslie Miller
Chief Medical Officer

Mark Cunningham
Chief Advisor CardioThoracic Surgery

Nic Chronos
Chief Advisor Research

Todd Seiger
Chief Advisor Reimbursement

Tom Newman
Associate Director Physician Relations

Michael Williams
Chief Advisor Implant Design Engineering

CAUTION Disclaimer and Warning: Products described on this web site are in early stage development and are not yet proven safe or effective in statistically significant controlled clinical studies. Any statement or phrases implying efficacy or safety in any form are considered modified by “intended to” or “designed to”. Investigational use only in countries where investigation is permitted by law and proper filings have been made and appropriate regulatory clearances have been granted. Any use of the product(s) must be in an authorized clinical study with institutional review board (ethics committee) approval and proper patient consent procedures followed. For other countries product is only available for laboratory investigation by credentialed institutions and investigators with proper clearances with a research agreement in place with a study sponsor. NOT AVAILABLE FOR SALE.